

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
160228	19/EM/0062	256447	Efficacy and Safety of ST-0529 in Subjects with Ulcerative Colitis	No		20			23/11/2018	12/04/2019	12/04/2019	24/04/2019	02/05/2019		03/07/2019	E - Staff availability issues	issues with local histopathology analysis.	NHS Provider
160229	17/NE/0351	235420	Evaluation of the MCM5 ELISA in the diagnosis of Prostate Cancer	Yes	07/08/2019	22	77	99	09/04/2019	30/04/2019	02/01/2018	14/05/2019	22/05/2019		11/07/2019			
160230	19/EM/0141	260308	BE COMPLETE	No		154			11/12/2018	03/05/2019	31/07/2019	03/10/2019	04/10/2019		18/03/2020	J - Other	various queries during setup	Both
160231	19/EM/0142	260307	Efficacy & Safety of Bimekizumab in PsA	No		139			11/12/2018	03/05/2019	01/08/2019	19/09/2019	19/09/2019		18/03/2020	J - Other	various queries during setup	Both
160232	19/YH/0072	257713	B7451036	No		70			27/11/2018	08/05/2019	11/07/2019	01/07/2019	17/07/2019		18/09/2019	A - Permissions delayed/denied C - Closed by sponsor J - Other	SIV rescheduled by sponsor numerous times from June to Sept leading to a	Sponsor
160233	19/SC/0204	260266	Phase 2 Dose-finding UC Study	No					18/03/2019	16/08/2019	08/07/2019			Site declined to participate		E - Staff availability issues	PI abandoned due to Capacity issues	NHS Provider
160234	19/NW/0328	263312	BMS-986165 in Moderate to Severe Ulcerative Colitis	No		28			16/05/2019	17/09/2019	23/07/2019	14/10/2019	15/10/2019		24/10/2019			Please Select...
160235	19/NE/0152	260824	Evolocumab Athero-Risk study	Yes	15/01/2020	49	182	231	29/05/2019	29/05/2019	18/06/2019	11/06/2019	17/07/2019		24/09/2019	E - Staff availability issues	PI Capacity issues	NHS Provider
160236	19/LO/0397	243173	GALAXI	No		15			10/04/2019	06/06/2019	05/06/2019	14/06/2019	21/06/2019		25/10/2019	D - Sponsor Delays	setup delays	Sponsor
160237	19/WM/0204	261470	52-Week Phase 2b/3 Crohn's Disease Study	No					18/06/2019	28/06/2019	18/06/2019			Site declined to participate		E - Staff availability issues	PI abandoned due to Capacity issues	NHS Provider
160238	19/LO/0697	250792	Regeneron 1011448 EoE study	No		27			30/07/2019	18/07/2019	12/07/2019	05/08/2019	14/08/2019		23/10/2019			
160239	19/YH/0400	271539	DIAMOND Study	No		77			14/11/2019	14/11/2019	09/01/2020	29/01/2020	30/01/2020			J - Other	delayed start to to COVID-19	Neither
160240	19/WM/0266	266172	Treatment of Hidradenitis Suppurativa Evaluation Study	No		40			11/10/2019	30/01/2020	03/10/2019	30/01/2020	10/03/2020		10/03/2020			
160241	19/LO/0750	258725	IBD-BOOST TRIAL	No		15			22/08/2019	13/01/2020	16/07/2019	13/01/2020	28/01/2020					
160242	19/WA/0365	261306	CAN457M230 1E1 (SUN Extension) Secukinumab in hidradenitis suppurativa	No					04/03/2020	04/03/2020	23/01/2020							
160243	19/LO/0236	230338	EFFORT Trial	No		1			11/09/2019	04/03/2020	01/07/2019	05/03/2020	05/03/2020					
160244	20/EE/0101	281712	RECOVERY trial	Yes	02/04/2020	9	6	15	18/03/2020	18/03/2020	17/03/2020	27/03/2020	27/03/2020		31/03/2020			